Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

UTILITY PATENT APPLICATION TRANSMITTAL

Attorney Docket No. 0125-UTL

First Inventor DREON, Darlene M.

Compositions & Methods for Reduction of Inflammato

Title

(Only for new nonprovisio	nal applications under 37 CFR 1.53(b)) E)	press Mail Label No	FA3	166259910			
APPLICATION ELEMENTS			ADDRESS TO: Assistant Commissioner for Patents Box Patent Application					
	cerning utility patent application conte	ents.		Washington,	DC 20231			
Applicant claims s See 37 CFR 1.27 Specification (preferred arrangement - Descriptive title - Cross Reference - Statement Reg - Reference to see or a computer p - Background of	[Total Pages 64] Int set forth below) In of the invention of the invent		7. CD-ROM or CD-R in duplicate, large table of Computer Program (Appendix) 8. Nucleotide and/or Amino Acid Sequence Submission (if applicable, all necessary) a. Computer Readable Form (CRF) b. Specification Sequence Listing on: i. CD-ROM or CD-R (2 copies); or ii. paper c. Statements verifying identity of above copies					
	n of the Drawings (if filed)		ACCOMPANYII	NG APPLIC	CATION PARTS			
- Detailed Descri - Claim(s) - Abstract of the	Disclosure	9. Assignment Papers (cover sheet & document(s)) 10. 37 CFR 3.73(b) Statement Power of Attorney						
4. Prawing(s) (35 U	I.S.C. 113) [Total Sheets 3	_ j	1 -		ent (if applicable) Copies of IDS			
5. Oath or Declaration a. Newly execution Copy from a]]	12. Statement (IDS)/PTO-1449 Citations 13. Preliminary Amendment						
b. (for continua))	Return Receipt Postcard (MPEP 503) (Should be specifically itemized)						
Signed sta named in t 1.63(d)(2)	ATON OF INVENTOR(S) Interment attached deleting inventor(s) the prior application, see 37 CFR and 1.33(b). Sheet. See 37 CFR 1.76	15. Certified Copy of Priority Document(s) (if foreign priority is claimed) 16. Nonpublication Request under 35 U.S.C. 122 (b)(2)(B)(i). Applicant must attach form PTO/SB/35 or its equivalent.						
The state of the s	•	17. Other:						
18. If a CONTINUING APPLICATION, check appropriate box, and supply the requisite information below and in a preliminary amendment, or in an Application Data Sheet under 37 CFR 1.76: Continuation Divisional Continuation-in-part (CIP) Of prior application No: From Application information: Examiner: For CONTINUATION OR DIVISIONAL APPS only: The entire disclosure of the prior application, from which an oath or declaration is supplied under								
Box 5b, is considered a part of the disclosure of the accompanying continuation or divisional application and is hereby incorporated by reference. The incorporation can only be relied upon when a portion has been inadvertently omitted from the submitted application parts.								
19. CORRESPONDENCE ADDRESS								
Customer Number or Bar Code Label (Insert Customer Number or Bar Code Label) or Correspondence address below								
Name	Michelle Y. Walker 32	2004			,			
	Galileo Pharmaceuticals, Inc.	ANTIMAKK O	Trice					
Address	5301 Patrick Henry Drive							
City	Santa Clara	Sta	ate CA	Zip C	1			
Country	USA	Telepho	one 408-654-5830x	179 Fa	408-654-5831			
Name (Print/Type)	Michelle Y. Walker		Registration No. (Atto	rney/Agent)	53,903			
Signature	Deetell)			Date	07/02/2003			

Burden Hour Statement: This form is estimated to take 6.2 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Box Patent Application, Washington, DC 20231.

02 July 2003

PTO/SB/17 (05-03)

Approved for use through 04/30/2003. OMB 0651-0032

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

FEE TO ANG		Complete if Known			
FEE TRANS	DIVILLIAL	Application Number	unknown		
for FY 2	2002	Filing Date	02 July 2003		
Effective 01/01/2003. Patent fees are si		First Named Inventor	DREON, Darlene M.		
		Examiner Name	unknown		
Applicant claims small entity status.	See 37 CFR 1.27	Art Unit	unknown		
TOTAL AMOUNT OF PAYMENT	(\$) 945.00	Attorney Docket No.	0125-UTL		

METHOD OF PAYMENT (check all that apply)					FEE CALCULATION (continued)							
Check Credit card Money Other None					3. ADDITIONAL FEES							
Large Entity Small Entity												
Deposit Acc		47			Fee Code	Fee (\$)	Fee Code	Fee (\$)	Fee [Description		Fee Paid
Account 5 Number	0-22	4 <i>7</i> ====			1051	130	2051	65	Surcharge - late	filing fee or oath		
Deposit Account G	Deposit Account Galileo Pharmaceuticals,				1052	50	2052	25	Surcharge - late cover sheet	provisional filing fe	e or	
Name The Director is authorized to: (check all that apply)				1053	130	1053		Non-English spe				
Charge fee(s) indicated below Credit any overpayments				1812	2,520	1812	2,520	For filing a reque	est for ex parte ree	xamination		
Charge any additional fee(s) during the pendency of this application				1804	920*	1804	920*	Requesting public Examiner action	lication of SIR prior	to		
Charge fee(s) indicated below, except for the filing fee to the above-identified deposit account.			1805	1,840*	1805	1,840*	Requesting pub Examiner action	lication of SIR after	г			
FEE CALCULATION				1251	110	2251	55	Extension for re	ply within first mon	th		
			1252	410	2252	205	Extension for re	eply within second r	nonth			
1. BASIC FILING FEE Large Entity Small Entity			1253	930	2253	465	Extension for re	ply within third mo	nth			
Fee Fee Fee	Fee		ee Description	Fee Paid	1254	1,450	2254	725	Extension for re	ply within fourth m	onth	
***	de (\$) 01 37	5	Utility filing fee		1255	1,970	2255	985	Extension for re	ply within fifth mon	ith	
	02 16		Design filing fee	3/5.00								
1003 520 200			Plant filing fee		1402	320	2402	160	160 Filing a brief in support of an appeal			
1004 750 200			Reissue filing fee		1403	280	2403	140	40 Request for oral hearing			
	05 8		Provisional filing fe	e	1451	1,510	1451	1,510	10 Petition to institute a public use proceeding			
SUBTOTAL (1) (\$) 375.00				1452	110	2452	55	Petition to revive	e - unavoidable			
				1453	1,300	2453	650	Petition to reviv	e - unintentional	-		
2. EXTRA CLA	AIM F	EES		AND REISSUE	-1501	1,300	2501	650	Utility issue fee	(or reissue)		
Extra Claims Fee from below Fee Paid Total Claims 74 $-20** = 54$ \times 9 $= 486$				1502	470	2502	235	Design issue fe	e			
				1503	630	2503	315	Plant issue fee				
Independent			1460	130	1460	130	Petitions to the	Commissioner				
Multiple Dependent				1807	50	1807	7 50	Processing fee	under 37 CFR 1.13	7(q)		
Large Entity Small Entity			. 1806	180	1806	3 180	Submission of I	nformation Disclosi	ure Stmt			
Code (\$)	Fee i Code	(\$)	Fee Descriptio	_	8021	40	802 ⁻	1 40	Recording each property (times	patent assignment	t per es)	:
1202 18	2202	9	Claims in excess		1809	750	2809	375	Filing a submiss	sion after final rejec	•	
1201 84	2201	42	Independent clain						(37 CFR 1.129(a))			
1203 280	2203		• •	nt claim, if not paid	1810	750	2810	375	5 For each additional invention to be examined (37 CFR 1.129(b))			
1204 84	2204	42	** Reissue indepe over original pa		1801	750	2801	375	•	ontinued Examinati	on (RCE)	
1205 18	2205	9	** Reissue claims and over origina		1802	900	1802	900	Request for ex of a design app	pedited examination	on	
(a) 570 00				Other	fee (sp	ecify) _					LI	
**or number previously paid, if greater, For Reissues, see above			*Redu	uced by	Basic	Filing F	ee Paid S	SUBTOTAL (3)	(\$),60			
									(Complete (if applic			
SUBMITTED BY			F	Registra	tion No			· · · · · · · · · · · · · · · · · · ·				
Name (Print/Type) Michelle Y. Walker				Attomev/		53,	,903	Telephone 408-	654-5830			

WARNING: Information on this form may become public. Credit card information should not be included on this form. Provide credit card information and authorization on PTO-2038.

This collection of information is required by 37 CFR 1.17 and 1.27. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Signature